CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 249 enrolled / 249 target
Drug / intervention
Dactinomycin +4 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00945009
NCT00945009Phase 3CompletedMonitor (1.2/mo)Completion was 113mo ago

Treatment for Patients With Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor

Children's Oncology Group·interventional·Posted Jul 23, 2009·Updated Jun 3, 2026

In Brief

A Phase 3 clinical trial evaluating Dactinomycin, Doxorubicin Hydrochloride, and 3 other interventions for Adult Kidney Wilms Tumor and 9 related conditions. Completed, enrolled 249 participants across 169 sites in 6 countries.

Signals

Enrolling slower than its timeline implies

Detailed Summary

This phase III trial studies how well combination chemotherapy and surgery work in treating young patients with Wilms tumor. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving it after surgery may kill any tumor cells that remain after surgery.

Study Details

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 23, 2009
Enrollment StartAug 24, 2009
Primary CompletionDec 31, 2016
Study CompletionMar 31, 2026
TodayJul 2, 2026
Enrollment to primary: 7.4 yearsPosted 16.9 years ago

Arms & Interventions

Arm 1 (Bilateral Wilms Tumors)experimental

Patients start with three drug chemotherapy (Regimen VAD; vincristine, dactinomycin and doxorubicin) and are evaluated and six and 12 weeks for feasibility of undergoing a partial nephrectomy/renal sparing surgery. At week 12 definitive surgery takes place followed by chemotherapy and radiation therapy based on histology and stage. Treatment continues for 25 or 31 weeks depending on histology. Patients are followed for up to 10 years following end of therapy.

Biological: DactinomycinDrug: Doxorubicin HydrochlorideRadiation: Radiation TherapyProcedure: Therapeutic Conventional SurgeryDrug: Vincristine Sulfate
Arm 2 (Unilateral High Risk tumors bilaterally predisposed)experimental

Patients start with either 2 drug or three drug chemotherapy (Regimen VA, VAD) and are evaluated a 6 and 12 weeks for feasibility of undergoing a partial nephrectomy. At week 12 definitive surgery takes place followed by chemotherapy.

Biological: DactinomycinDrug: Doxorubicin HydrochlorideRadiation: Radiation TherapyProcedure: Therapeutic Conventional SurgeryDrug: Vincristine Sulfate
Arm 3 (DHPLN)experimental

Patients with this rare disease are diagnosed based on cross-sectional imaging characteristics and undergo 2 drug chemotherapy (Regimen;VA). Patients are reassessed at 6 weeks and 12 weeks. If disease has responded or stayed stable chemotherapy is completed for 19 weeks (Regimen EE4A). If disease has progress a biopsy is performed to assess histology and adjust therapy based on the biopsy. This therapy may include, nephrectomy, chemotherapy or radiation therapy.

Biological: DactinomycinDrug: Doxorubicin HydrochlorideRadiation: Radiation TherapyProcedure: Therapeutic Conventional SurgeryDrug: Vincristine Sulfate

Interventions

Dactinomycinbiological

Given IV

Doxorubicin Hydrochloridedrug

Given IV

Radiation Therapyradiation

Undergo radiation therapy

Therapeutic Conventional Surgeryprocedure

Undergo surgical resection

Vincristine Sulfatedrug

Given IV